Novartis is trading 3.12% down at $155 in after-hours trading after pausing eight autoimmune and neurological rap-cel trials following three patient deaths.
- Reuters reported the halt followed fatal cases of a severe immune reaction.
- Novartis is conducting a comprehensive safety review with independent boards.
- The negative catalyst likely outweighed the recent Alteogen drug-delivery deal, while broader market weakness added pressure.